27 results
8-K
MLYS
Mineralys Therapeutics Inc
10 Jun 24
Other Events
4:02pm
; the Company’s ability to evaluate lorundrostat as a potential treatment for chronic kidney disease or uncontrolled hypertension; the planned future
8-K
EX-99.1
MLYS
Mineralys Therapeutics Inc
9 May 24
Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
7:07am
), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases … of an aldosterone targeted treatment approach with lorundrostat has the potential to benefit millions of patients who are impacted by hypertension, chronic
424B5
MLYS
Mineralys Therapeutics Inc
11 Apr 24
Prospectus supplement for primary offering
4:35pm
aldosterone, including hypertension and chronic kidney disease (CKD). In the United States, there are over 115 million patients who have sustained elevated … elevated aldosterone, including hypertension and chronic kidney disease (CKD). In the United States, there are over 115 million patients who have
8-K
EX-99.1
MLYS
Mineralys Therapeutics Inc
21 Mar 24
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
7:43am
), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven … for the treatment of hypertension, as well as adjacent conditions including chronic kidney disease,” stated Jon Congleton, Chief Executive Officer
S-3
7d1d2w28
21 Mar 24
Shelf registration
7:30am
8-K
EX-99.1
heazff
8 Feb 24
Mineralys Therapeutics Announces $120 Million Private Placement Financing
4:41pm
8-K
EX-99
sjesj8w2ql17kz7snr
4 Jan 24
Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer
4:10pm
8-K
EX-99.1
05to0lv b5
22 Dec 23
Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
9:04am
8-K
EX-99.1
yz3 adi7gdf
13 Nov 23
Regulation FD Disclosure
8:20am
8-K
cydp r23lel6s0j2i
13 Nov 23
Regulation FD Disclosure
8:20am
8-K
EX-99.1
8jmxd3ct1ira
7 Nov 23
Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:07pm
8-K
EX-99.1
wt65pcc3b
2 Nov 23
Regulation FD Disclosure
10:06am
8-K
EX-99.1
1hq93t43
7 Aug 23
Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:08pm
8-K
aqb hvrjco4
17 Jul 23
Regulation FD Disclosure
4:03pm
8-K
EX-99.1
b9ahtxagysc7u10v4m
17 Jul 23
Regulation FD Disclosure
4:03pm
10-Q
5akh3uppk1xj
15 May 23
Quarterly report
5:25pm